文献速递消化道肿瘤与早癌

间质型肿瘤且梭杆菌目高丰度的结直肠癌患者预后更差

Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC).
PubMed 文献 · Gut · 2021-09-08

该研究结合细胞实验与两个独立结直肠癌队列(Taxonomy n=140;TCGA-COAD-READ n=605),分析梭杆菌目丰度与CMS/CRIS亚型、免疫浸润及预后的关系。结果发现间质型(CMS4/CRIS-B)肿瘤且梭杆菌目高丰度患者预后更差风险约高两倍,非间质型患者中该关联不存在。

要点

  • 间质型(CMS4/CRIS-B)结直肠癌合并高梭杆菌目丰度者预后更差风险约高两倍。
  • 高Fn/Fusobacteriales多见于CMS1、微卫星不稳定肿瘤,伴M1巨噬细胞浸润及IL-6/IL-8/IL-1β信号升高。
  • 非间质型患者中梭杆菌目丰度与预后无显著关联,提示需按分子亚型分层。

核心结论

  • CMS4/CRIS-B且高Fn/Fusobacteriales丰度的结直肠癌患者为高危亚群,可能受益于靶向间质生物学的治疗。

研究设计与样本

  • 研究耦合细胞培养实验与两个独立结直肠癌患者队列的Fn/Fusobacteriales丰度及宿主生物学/微环境特征分析。
  • Taxonomy队列n=140(结肠和直肠病例),TCGA-COAD-READ队列n=605。

主要发现

  • 体外实验中,Fn感染通过NF-κB/TNF-α在HCT116和HT29细胞系诱导炎症。
  • 患者中高Fn/Fusobacteriales见于CMS1、微卫星不稳定肿瘤,伴M1巨噬细胞浸润、M2巨噬细胞减少及IL-6/IL-8/IL-1β信号升高。
  • Taxonomy队列提示Fn对CMS4/CRIS-B患者有预后价值,尽管其Fn载量低于CMS1患者。
  • TCGA-COAD-READ队列中,间质型(CMS4和/或CRIS-B)与非间质型(既非CMS4也非CRIS-B)患者中Fusobacteriales相对丰度与结局的关联不同。
  • 间质型肿瘤且高Fusobacteriales患者预后更差风险约高两倍,非间质型患者中该关联为零。

关键数值与推荐

  • 高Fn/Fusobacteriales见于CMS1、微卫星不稳定肿瘤,伴M1巨噬细胞浸润、M2巨噬细胞减少及IL-6/IL-8/IL-1β信号升高。

临床怎么用

  • 对结直肠癌患者可结合分子亚型(CMS4/CRIS-B)与Fn/Fusobacteriales丰度识别高危亚群。
  • 间质型且高梭杆菌目丰度患者可能适合靶向间质生物学的治疗策略。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Transcriptomic-based subtyping, consensus molecular subtyping (CMS) and colorectal cancer intrinsic subtyping (CRIS) identify a patient subpopulation with mesenchymal traits (CMS4/CRIS-B) and poorer outcome. Here, we investigated the relationship between prevalence of Fusobacterium nucleatum (Fn) and Fusobacteriales, CMS/CRIS subtyping, cell type composition, immune infiltrates and host contexture to refine patient stratification and to identify druggable context-specific vulnerabilities. DESIGN: We coupled cell culture experiments with characterisation of Fn/Fusobacteriales prevalence and host biology/microenviroment in tumours from two independent colorectal cancer patient cohorts (Taxonomy: n=140, colon and rectal cases of The Cancer Genome Atlas (TCGA-COAD-READ) cohort: n=605). RESULTS: In vitro, Fn infection induced inflammation via nuclear factor kappa-light-chain-enhancer of activated B cells/tumour necrosis factor alpha in HCT116 and HT29 cancer cell lines. In patients, high Fn/Fusobacteriales were found in CMS1, microsatellite unstable () tumours, with infiltration of M1 macrophages, reduced M2 macrophages, and high interleukin (IL)-6/IL-8/IL-1β signalling. Analysis of the Taxonomy cohort suggested that Fn was prognostic for CMS4/CRIS-B patients, despite having lower Fn load than CMS1 patients. In the TCGA-COAD-READ cohort, we likewise identified a differential association between Fusobacteriales relative abundance and outcome when stratifying patients in mesenchymal (either CMS4 and/or CRIS-B) versus non-mesenchymal (neither CMS4 nor CRIS-B). Patients with mesenchymal tumours and high Fusobacteriales had approximately twofold higher risk of worse outcome. These associations were null in non-mesenchymal patients. Modelling the three-way association between Fusobacteriales prevalence, molecular subtyping and host contexture with logistic models with an interaction term disentangled the pathogen-host signalling relationship and identified aberrations (including NOTCH, CSF1-3 and IL-6/IL-8) as candidate targets. CONCLUSION: This study identifies CMS4/CRIS-B patients with high Fn/Fusobacteriales prevalence as a high-risk subpopulation that may benefit from therapeutics targeting mesenchymal biology.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Salvucci M, Crawford N, Stott K, et al. Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC). Gut. 2021. PMID: 34497144. doi:10.1136/gutjnl-2021-325193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。